Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

First personalised vaccines shows promise for skin cancer

10 July 2017

By Meetal Solanki

Appeared in BioNews 908

A revolutionary vaccine uses the patient's own immune response to target tumour cells and could be the first step in bespoke, precision medicine

Researchers in two separate studies, both published in Nature, have targeted newly found proteins on the surface of tumour cells which are not present in healthy tissue. These 'neo-antigens' normally arise from genetic mutation within the tumour cells which means to they are unique only to those cells. 

A sample is taken from each individual patient and sequenced to determine exactly which genetic mutations are present and hence what mutated proteins. Researchers then use software to predict which proteins are more likely to give a strong immune response.

'What's really exciting about this approach is that it involves sequencing their tumour and making a bespoke, customised vaccine,' says Professor Kevin Harrington of The Institute of Cancer Research in London, who was not involved in the research. 'When we have previously given vaccines, we have taken a generic approach and it was a bit hit-and-miss.'

Dr Catherine Wu from the Dana-Farber Cancer Institute in Boston injected a combination of up to 20 of these mutated neo-antigens into the skin of six patients with melanoma who were deemed at a high risk of cancer recurrence. Of the six, four showed no recurrences of tumour growth after two years

Instead of injecting proteins to elicit an immune response, researchers lead by Professor Ugur Sahin at German firm BioNTech, injected RNA encoding up to 10 mutated proteins into 13 patients. Cells use RNA as a template to make proteins, in this case the selected mutated proteins. Both techniques yielded similar results with eight out the thirteen patients injected having no cancer recurrence.

In addition in both studies 'a plan B' was also adopted where individuals whose cancer has developed further despite treatment were given a checkpoint inhibitor called PD-1 which blocks tumours from evading immune system attacks. This was shown to completely wipe out the tumour.

The difficulty facing cancer researchers has long been how to kill tumour cells whilst also sparing healthy tissue. Conventional therapies such as chemotherapy which target rapidly dividing cells are toxic to many healthy cell types and can have significant side effects.

In this new approach, the immune system – in particular the T (white blood) cells– become sensitised to the tumour-specific proteins and only attack cancer cells, leaving healthy cells untouched.

Although this method might work with any kind of cancer, skin tumours may be more vulnerable to immune attack. 'You could in theory vaccinate any tumour type,' Harrington says, 'but some will be more amenable to this sort of approach than others.'

Aside from the need for larger trials, one current hurdle is that the vaccines take around three months to produce which for some cancers may be too late.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

30 May 2017 - by Shaoni Bhattacharya 
The first cancer drug based on a specific genetic feature has been approved by the US drugs regulator...
13 June 2016 - by Rachel Reeves 
Genetic sequencing leading to targeted treatment significantly improves cancer patient outcomes in early-stage clinical trials, according to a study...
24 August 2015 - by Kirsty Oswald 
Researchers have shown that a skin cancer drug can be used to treat advanced lung cancer in patients whose tumours harbour a particular mutation...
13 April 2015 - by Dr Nicoletta Charolidi 
A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour antibodies has shown early signs of promise...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation